

Press Release

2021

1st of October

ISR strengthens the organization

ISR Immune System Regulation Holding AB (publ) strengthens management as part of strategic development of the company.

The company employs Johan Sjö Dahl as Chief Scientific Officer (CSO) to lead R&D in the company. Johan comes with experience in pharmaceutical and medical product development from Orkla, Bactiguard and BioArctic.

As CFO and COO, Jonas Winqvist is a consultant from Implement Consulting Group to strengthen financial and operational management of the Group.

In order to meet the regulatory requirements for pharmaceutical companies, we also hire Johanna Jonsson as quality manager. Johanna has experience from the pharmaceutical industry with a background in AstraZeneca and SOBI.

"It is natural to bring resources and expertise into the company now that several clinical study programs in parallel with preclinical development are underway. The company is in an expansion phase and now needs to tie competences in house to streamline research, development to mature into a marketing company.", comments Ola Winqvist, CEO ISR.

ISR Immune System Regulation Holding AB (publ) is a pharmaceutical company that conducts research, development and is in phase II drug testing. The company develops its own candidates, renews indications for diseases where the immune system has a central role. Development takes place in the areas of HIV, Hepatitis B, immuno-oncology and vaccines.

For further information, please contact:

Ola Winqvist

CEO, ISR Immune System Regulation Holding AB (publ)

E-post: ola.winqvist@israb.se

Phone: +46 (0)70 5427939

About ISR Immune System Regulation Holding AB (publ)

ISR is an innovation driven pharmaceutical development company within immunotherapy. The company focuses on clinical and preclinical research, with the goal to develop a broad-spectrum antiviral platform of immune regulating pharmaceuticals. Mangold is the company's Certified Adviser, and can be reached on phone +46 (0)8-463 80 00.

www.israb.se

This information is subject to compulsory publication by Immune System Regulation Holding AB (publ) complying with EU's Market Abuse Regulation (MAR), and the Market Abuse Act